Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 3
1950 1
1951 2
1971 2
1972 1
1975 1
1978 2
1979 2
1980 4
1983 3
1984 3
1985 3
1986 3
1987 4
1988 6
1989 3
1990 6
1991 6
1992 3
1993 2
1994 5
1995 7
1996 6
1997 7
1998 13
1999 10
2000 9
2001 10
2002 10
2003 9
2004 10
2005 12
2006 18
2007 15
2008 14
2009 19
2010 21
2011 13
2012 9
2013 13
2014 13
2015 18
2016 21
2017 13
2018 13
2019 21
2020 20
2021 22
2022 19
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
Toll-like receptor signalling in B cells during systemic lupus erythematosus.
Fillatreau S, Manfroi B, Dörner T. Fillatreau S, et al. Nat Rev Rheumatol. 2021 Feb;17(2):98-108. doi: 10.1038/s41584-020-00544-4. Epub 2020 Dec 18. Nat Rev Rheumatol. 2021. PMID: 33339987 Free PMC article. Review.
B lymphocytes have a central role in autoimmune diseases, which are often defined by specific autoantibody patterns and feature a loss of B cell tolerance. A prototypic disease associated with B cell hyperactivity is systemic lupus erythematosus (SLE). In pat …
B lymphocytes have a central role in autoimmune diseases, which are often defined by specific autoantibody patterns and feature a los …
Vitamin B(12).
[No authors listed] [No authors listed] 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30489717 Free Books & Documents. Review.
Low doses (1 to 10 mcg) of vitamin B(12) found in B complex or prenatal vitamins increase milk levels only slightly. Higher daily doses of 50 to 250 mcg are needed in cases of maternal deficiency. The breastfed infant is not exposed to excessive vitamin B(12) …
Low doses (1 to 10 mcg) of vitamin B(12) found in B complex or prenatal vitamins increase milk levels only slightly. Higher da …
The Diagnosis and Treatment of Sjögren's Syndrome.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. Stefanski AL, et al. Dtsch Arztebl Int. 2017 May 26;114(20):354-361. doi: 10.3238/arztebl.2017.0354. Dtsch Arztebl Int. 2017. PMID: 28610655 Free PMC article. Review.
The disease also markedly elevates the risk of non-Hodgkin lymphoma of the B-cell series, which arises in about 5% of patients. Primary Sjogren's syndrome (pSS) differs from the secondary form (sSS), which appears in the setting of another autoimmune disease, particularly …
The disease also markedly elevates the risk of non-Hodgkin lymphoma of the B-cell series, which arises in about 5% of patients. Prima …
B cells in systemic lupus erythematosus.
Szelinski F, Lino AC, Dörner T. Szelinski F, et al. Curr Opin Rheumatol. 2022 Mar 1;34(2):125-132. doi: 10.1097/BOR.0000000000000865. Curr Opin Rheumatol. 2022. PMID: 34939607 Review.
RECENT FINDINGS: SLE carries characteristic B cell abnormalities, which offer new insights into B cell differentiation and their disturbances including discoveries of pathogenic B cell subsets and intrinsic B cell abnormalities. ...SUMMARY: Identificat …
RECENT FINDINGS: SLE carries characteristic B cell abnormalities, which offer new insights into B cell differentiation and the …
Immunopathogenic mechanisms of systemic autoimmune disease.
Wahren-Herlenius M, Dörner T. Wahren-Herlenius M, et al. Lancet. 2013 Aug 31;382(9894):819-31. doi: 10.1016/S0140-6736(13)60954-X. Lancet. 2013. PMID: 23993191 Review.
Type 1 interferon produced by innate immune cells has a central role in systemic autoimmunity and activates B cells and T cells. In turn, B-cell-derived autoantibodies stimulate dendritic cells to produce type 1 interferon; thus, a positive feedforward loop is forme …
Type 1 interferon produced by innate immune cells has a central role in systemic autoimmunity and activates B cells and T cells. In t …
Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ. Dörner T, et al. Ann Rheum Dis. 2019 May;78(5):641-647. doi: 10.1136/annrheumdis-2018-214720. Epub 2019 Mar 2. Ann Rheum Dis. 2019. PMID: 30826774 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjogren's syndrome (pSS) in a double-blind, placebo-controlled, phase II, sing …
OBJECTIVES: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-b …
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the pri …
BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful …
B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives.
Dang VD, Stefanski AL, Lino AC, Dörner T. Dang VD, et al. J Invest Dermatol. 2022 Mar;142(3 Pt B):811-822. doi: 10.1016/j.jid.2021.05.038. Epub 2021 Dec 24. J Invest Dermatol. 2022. PMID: 34955289 Free article. Review.
In this study, we review the key findings that define subsets of B and plasma cells with pathogenic and protective functions in autoimmunity. In addition to harsh B-cell depletion, we discuss the strategies that have the potential to reinstall the balance of pathoge …
In this study, we review the key findings that define subsets of B and plasma cells with pathogenic and protective functions in autoi …
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy. This dose-finding trial aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sj …
A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy. This dose-findi …
Guidelines for the use of flow cytometry and cell sorting in immunological studies.
Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings… See abstract for full author list ➔ Cossarizza A, et al. Eur J Immunol. 2017 Oct;47(10):1584-1797. doi: 10.1002/eji.201646632. Eur J Immunol. 2017. PMID: 29023707 Free PMC article. No abstract available.
435 results